Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/46082
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorCHINOCA, J.-
dc.contributor.authorANDRADE, D. S.-
dc.contributor.authorMENDES, A.-
dc.contributor.authorMARCHI, P. De-
dc.contributor.authorPRIETO, T. G.-
dc.contributor.authorBALDAVIRA, C. M.-
dc.contributor.authorFARHAT, C.-
dc.contributor.authorMARTINS, J. R. M.-
dc.contributor.authorNADER, H. B.-
dc.contributor.authorCARRARO, D. M.-
dc.contributor.authorCAPELOZZI, V. L.-
dc.contributor.authorSA, V de-
dc.date.accessioned2022-04-19T13:03:56Z-
dc.date.available2022-04-19T13:03:56Z-
dc.date.issued2022-
dc.identifier.citationBRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, v.55, n.1, article ID e11513, 9p, 2022-
dc.identifier.issn0100-879X-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/46082-
dc.description.abstractWe evaluated whether hyaluronan (HA) levels in the sputum could be used as a noninvasive tool to predict progressive disease and treatment response, as detected in a computed tomography scan in non-small cell lung cancer (NSCLC) patients. Sputum samples were collected from 84 patients with histological confirmation of NSCLC, 33 of which were in early-stage and 51 in advanced-stage disease. Patients received systemic chemotherapy (CT) after surgery (n=36), combined CT and immunotherapy (10) (n=15), or targeted therapy for driver mutation and disease relapse (N=4). The primary end-point was to compare sputum HA levels in two different concentrations of hypertonic saline solution with overall survival (OS) and the secondary and exploratory end-points were radiologic responses to treatment and patient outcome. Higher concentrations of HA in the sputum were significantly associated to factors related to tumor stage, phenotype, response to treatment, and outcome. In the early stage, patients with lower sputum HA levels before treatment achieved a complete tumor response after systemic CT with better progression-free survival (PFS) than those with high HA levels. We also examined the importance of the sputum HA concentration and tumor response in the 51 patients who developed metastatic disease and received CT + IO. Patients with low levels of sputum HA showed a complete tumor response in the computed tomography scan and stable disease after CT + IO treatment, as well as a better PFS than those receiving CT alone. HA levels in sputum of NSCLC patients may serve as a candidate biomarker to detect progressive disease and monitor treatment response in computed tomography scans.eng
dc.description.sponsorshipSao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/26642-4, 2018/20403-6]-
dc.language.isoeng-
dc.publisherASSOC BRAS DIVULG CIENTIFICAeng
dc.relation.ispartofBrazilian Journal of Medical and Biological Research-
dc.rightsopenAccesseng
dc.subjectSputumeng
dc.subjectLung cancereng
dc.subjectHyaluronaneng
dc.subjectRadiologic responseeng
dc.subjectTreatment and outcomeeng
dc.subject.otherserumeng
dc.subject.othercteng
dc.titleMonitoring non-small cell lung cancer progression and treatment response through hyaluronic acid in sputumeng
dc.typearticleeng
dc.rights.holderCopyright ASSOC BRAS DIVULG CIENTIFICAeng
dc.identifier.doi10.1590/1414-431X2021e11513-
dc.identifier.pmid35320334-
dc.subject.wosBiologyeng
dc.subject.wosMedicine, Research & Experimentaleng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalCHINOCA, J.:AC Camargo Canc Ctr, Lab Genom & Biol Mol, Sao Paulo, SP, Brazil-
hcfmusp.author.externalANDRADE, D. S.:AC Camargo Canc Ctr, Lab Genom & Biol Mol, Sao Paulo, SP, Brazil-
hcfmusp.author.externalMENDES, A.:Univ Fed Sao Paulo, Dept Bioquim, Escola Paulista Med, Discipline Biol Mol, Sao Paulo, SP, Brazil-
hcfmusp.author.externalMARCHI, P. De:Hosp Amor Barretos, Dept Oncol Med, Sao Paulo, SP, Brazil-
hcfmusp.author.externalFARHAT, C.:Univ Sao Paulo, Fac Med, Dept Patol, Sao Paulo, SP, Brazil-
hcfmusp.author.externalMARTINS, J. R. M.:Univ Fed Sao Paulo, Dept Bioquim, Escola Paulista Med, Discipline Biol Mol, Sao Paulo, SP, Brazil; Univ Fed Sao Paulo, Lab Endocrinol Mol & Translac, Escola Paulista Med, Sao Paulo, SP, Brazil-
hcfmusp.author.externalNADER, H. B.:Univ Fed Sao Paulo, Dept Bioquim, Escola Paulista Med, Discipline Biol Mol, Sao Paulo, SP, Brazil-
hcfmusp.author.externalCARRARO, D. M.:AC Camargo Canc Ctr, Lab Genom & Biol Mol, Sao Paulo, SP, Brazil-
hcfmusp.author.externalSA, V de:AC Camargo Canc Ctr, Lab Genom & Biol Mol, Sao Paulo, SP, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, Sao Paulo, SP, Brazil-
hcfmusp.description.articlenumbere11513-
hcfmusp.description.issue1-
hcfmusp.description.volume55-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000773742300001-
hcfmusp.origem.id2-s2.0-85124542703-
hcfmusp.publisher.cityRIBEIRAO PRETOeng
hcfmusp.publisher.countryBRAZILeng
hcfmusp.relation.referenceAbatangelo G, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071743eng
hcfmusp.relation.referenceAberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873eng
hcfmusp.relation.referenceAhmed N, 2021, CANCERS, V13, DOI 10.3390/cancers13123012eng
hcfmusp.relation.referenceAhmed N, 2016, MAGN RESON INSIGHTS, V9, P29, DOI 10.4137/MRI.S40864eng
hcfmusp.relation.referenceBach PB, 2012, JAMA-J AM MED ASSOC, V307, P2418, DOI 10.1001/jama.2012.5521eng
hcfmusp.relation.referenceCairns RA, 2011, COLD SH Q B, V76, P299, DOI 10.1101/sqb.2011.76.012856eng
hcfmusp.relation.referenceCreaney J, 2013, LUNG CANCER, V82, P491, DOI 10.1016/j.lungcan.2013.09.016eng
hcfmusp.relation.referenceDELPECH B, 1985, ANAL BIOCHEM, V149, P555, DOI 10.1016/0003-2697(85)90613-Xeng
hcfmusp.relation.referenceGarantziotis S, 2009, J BIOL CHEM, V284, P11309, DOI 10.1074/jbc.M802400200eng
hcfmusp.relation.referenceGoldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009eng
hcfmusp.relation.referenceHanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013eng
hcfmusp.relation.referenceHirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8eng
hcfmusp.relation.referenceHuang GL, 2018, J CONTROL RELEASE, V278, P122, DOI 10.1016/j.jconrel.2018.04.015eng
hcfmusp.relation.referenceKobayashi T, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111525eng
hcfmusp.relation.referenceCarro LM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102210eng
hcfmusp.relation.referenceMartins JRM, 2003, ANAL BIOCHEM, V319, P65, DOI 10.1016/S0003-2697(03)00251-3eng
hcfmusp.relation.referenceO'Connor JPB, 2011, BRIT J RADIOL, V84, pS112, DOI 10.1259/bjr/55166688eng
hcfmusp.relation.referenceRangel MP, 2015, BRAZ J MED BIOL RES, V48, P557, DOI 10.1590/1414-431X20144300eng
hcfmusp.relation.referenceReich JM, 2019, J THORAC IMAG, V34, P154, DOI 10.1097/RTI.0000000000000406eng
hcfmusp.relation.referenceSILVERBERG E, 1984, CA-CANCER J CLIN, V34, P7eng
hcfmusp.relation.referenceStern R, HYALURONIC CANC BIOLeng
hcfmusp.relation.referenceVeiseh M, 2014, P NATL ACAD SCI USA, V111, pE1731, DOI 10.1073/pnas.1402383111eng
hcfmusp.relation.referenceWang DR, 2016, ONCOTARGET, V7, P39957, DOI 10.18632/oncotarget.9554eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1414-431X-
hcfmusp.citation.scopus0-
hcfmusp.scopus.lastupdate2022-07-07-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MPT
Departamento de Patologia - FM/MPT

Artigos e Materiais de Revistas Científicas - LIM/03
LIM/03 - Laboratório de Medicina Laboratorial


Files in This Item:
File Description SizeFormat 
art_CHINOCA_Monitoring_nonsmall_cell_lung_cancer_progression_and_treatment_2022.PDFpublishedVersion (English)583.11 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.